Amundi
BIO icon

Amundi’s Bio-Rad Laboratories Class A BIO Stock Holding History

Amundi’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.8M Buy
38,778
+36,697
+1,763% +$10.6M ﹤0.01% 868
2025
Q4 		$631K Buy
2,081
+31
+2% +$9.67K ﹤0.01% 1394
2025
Q3 		$634K Buy
2,050
+174
+9% +$47.4K ﹤0.01% 1264
2025
Q2 		$470K Sell
1,876
-21,460
-92% -$5.07M ﹤0.01% 1390
2025
Q1 		$5.48M Buy
23,336
+3,294
+16% +$991K ﹤0.01% 934
2024
Q4 		$6.9M Sell
20,042
-16,596
-45% -$5.63M ﹤0.01% 928
2024
Q3 		$12.4M Sell
36,638
-8,099
-18% -$2.57M ﹤0.01% 801
2024
Q2 		$12.1M Buy
44,737
+234
+0.5% +$68.1K ﹤0.01% 796
2024
Q1 		$12.5M Sell
44,503
-150,139
-77% -$49.4M 0.01% 789
2023
Q4 		$61.9M Buy
194,642
+111,698
+135% +$35M 0.03% 486
2023
Q3 		$28.6M Buy
82,944
+25,525
+44% +$9.85M 0.01% 635
2023
Q2 		$21.7M Sell
57,419
-41,944
-42% -$17.1M 0.01% 682
2023
Q1 		$46.1M Sell
99,363
-152,688
-61% -$71.5M 0.02% 520
2022
Q4 		$116M Buy
252,051
+78,235
+45% +$31.6M 0.06% 313
2022
Q3 		$79.3M Buy
173,816
+145,942
+524% +$72.8M 0.05% 393
2022
Q2 		$13.6M Sell
27,874
-9,063
-25% -$4.72M 0.01% 706
2022
Q1 		$22M Buy
36,937
+1,191
+3% +$718K 0.01% 634
2021
Q4 		$22.8M Buy
35,746
+30
+0.1% +$22.5K 0.01% 653
2021
Q3 		$26.6M Buy
35,716
+763
+2% +$572K 0.02% 610
2021
Q2 		$22.5M Buy
+34,953
New +$21.3M 0.02% 645

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Amundi's BIO Position: Q1 2026 in Review

Amundi increased its Bio-Rad Laboratories Class A (BIO) stake by 1,763% in Q1 2026, buying an estimated $10.6M and bringing the position to 38,778 shares worth $10.8M. The position accounts for ﹤0.01% of the portfolio, ranked #868.

Amundi first reported a position in BIO in Q2 2021 and has held it in 20 quarters since. The position peaked at $116M in Q4 2022. 391 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

  • Amundi held 38,778 shares of Bio-Rad Laboratories Class A worth $10.8M as of Q1 2026.
  • Amundi bought 36,697 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $10.6M.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Amundi's portfolio in Q1 2026, its #868 holding.
  • Amundi first reported a position in Bio-Rad Laboratories Class A in Q2 2021 and has held it in 20 quarters since.
  • Amundi's Bio-Rad Laboratories Class A position peaked at $116M in Q4 2022.
  • 391 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on Amundi's 13F filing for Q1 2026, filed 18 May 2026.